Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 244

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia

Open access
Arabi, Yaseen M., Hajeer, Ali H., Luke, Thomas, Raviprakash, Kanakatte, Balkhy, Hanan, Johani, Sameera, Al-Dawood, Abdulaziz, Al-Qahtani, Saad, Al-Omari, Awad, Al-Hameed, Fahad, Hayden, Frederick G., Fowler, Robert, Bouchama, Abderrezak, Shindo, Nahoko, Al-Khairy, Khalid, Carson, Gail, Taha, Yusri, Sadat, Musharaf, Alahmadi, Mashail·2016·Emerging Infectious Diseases

Abstract

We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested samples, 12 (2.7%) had a reactive ELISA result, and 9 of the 12 had reactive indirect fluorescent antibody and microneutralization assay titers. Undertaking clinical trials of convalescent plasma for passive immunotherapy of MERS-CoV infection may be feasible, but such trials would be challenging because of the small pool of potential donors with sufficiently high antibody titers. Alternative strategies to identify convalescent plasma donors with adequate antibody titers should be explored, including the sampling of serum from patients with more severe disease and sampling at earlier points during illness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3201/eid2209.151164

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 244

Metadata

Authors
Arabi, Y. M., Hajeer, A. H., Luke, T., Raviprakash, K., Balkhy, H., Johani, S., Al-Dawood, A., Al-Qahtani, S., Al-Omari, A., Al-Hameed, F., Hayden, F. G., Fowler, R., Bouchama, A., Shindo, N., Al-Khairy, K., Carson, G., Taha, Y., Sadat, M., & Alahmadi, M.
Venue
Emerging Infectious Diseases
Published
2016-09
Volume
22
Issue
9
Pages
1554-1561
ISSN
  • 1080-6040 (ISSN-L)
  • 1080-6059
OpenAlex
W2460100043
Cited by
244
References
3
FWCI
7.84
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. https://app.cochat.ai/papers/10.3201/eid2209.151164
The paper
Arabi, Y. M., Hajeer, A. H., Luke, T., Raviprakash, K., Balkhy, H., Johani, S., Al-Dawood, A., Al-Qahtani, S., Al-Omari, A., Al-Hameed, F., Hayden, F. G., Fowler, R., Bouchama, A., Shindo, N., Al-Khairy, K., Carson, G., Taha, Y., Sadat, M., & Alahmadi, M. (2016). Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerging Infectious Diseases. https://doi.org/10.3201/eid2209.151164

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.